Sector News

BD pens $24B Bard buyout to create medtech powerhouse

April 25, 2017
Life sciences

BD has struck a $24 billion deal to buy C.R. Bard. The takeover will strengthen BD’s position in the markets for catheters, pumps and other items while also giving it a bigger presence in fast-growing fields including oncology and biosurgery.

Analysts at Jefferies said the acquisition would create “the undisputed leader in vascular access solutions.” This leadership position will be underpinned by BD’s portfolio of needles, syringes and other medication delivery devices and Bard’s peripherally inserted catheters and ports. BD, also known as Becton Dickinson, sees such breadth and scale strengthening its hand in a consolidating healthcare sector.

“We will be able to partner [with providers] on fundamental treatment processes in a way that no one else can,” Becton Dickinson CEO Vincent Forlenza told Reuters.

BD is borrowing heavily to make the deal happen. The med tech company will finance most of the cash portion of the deal with a $10 billion loan and a $4.5 billion sale of equities and other securities. BD will fund another tranche of the takeover by issuing $8 billion in new stock to Bard’s shareholders. To offset the outlay, BD aims to make cost savings of $300 million a year by 2020.

The buyout continues a busy few years for big med tech deals. Since Medtronic completed its $49.9 billion takeover of Covidien early in 2015, BD has bought CareFusion for $12.2 billion, Zimmer has landed Biomet for $14 billion and Abbott has acquired St. Jude Medical in a deal originally valued at $25 billion. If the BD-Bard deal closes as expected later this year, it will move the amount spent in big ticket med tech takeovers in the past few years well past the $100 billion mark. Shares in BD have risen 31% since it closed the CareFusion deal.

Some observers think there is scope and appetite for more big deals. Integra Lifesciences, Intuitive Surgical, Teleflex and Wright Medical have market caps ranging from just north of $1 billion to $30 billion and could come into play if other big med tech companies follow BD’s lead. Forlenza thinks that is a distinct possibility.

“We expect that this deal will cause others in the space to take a step back and ask themselves if there is an opportunity to do another large transaction and should we be acting upon it,” Forlenza said.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.